TY  - JOUR

T1  - Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 versus reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis

JO  - JBMR Plus

UR  - https://doi.org/10.1093/jbmrpl/ziag062

PY  - 2026/04/11

AU  - Eastell R

AU  - Orwoll E

AU  - Cosman F

AU  - Plebanski R

AU  - Kumar K

AU  - Marwah A

AU  - Deodhar SS

AU  - Wolff-Holz E

AU  - Loganathan S

ED  - 

DO  - DOI: 10.1093/jbmrpl/ziag062

PB  - Oxford University Press (OUP)

Y2  - 2026/04/26

ER  -